Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Sees Large Growth in Short Interest

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) saw a large growth in short interest during the month of April. As of April 30th, there was short interest totalling 4,920,000 shares, a growth of 6.7% from the April 15th total of 4,610,000 shares. Based on an average daily volume of 506,100 shares, the short-interest ratio is presently 9.7 days. Approximately 20.0% of the shares of the stock are sold short.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. HC Wainwright reiterated a "buy" rating and issued a $60.00 price objective on shares of Arcturus Therapeutics in a research note on Wednesday, March 20th. William Blair reiterated an "outperform" rating on shares of Arcturus Therapeutics in a research note on Friday, March 8th. Citigroup upped their price objective on shares of Arcturus Therapeutics from $40.00 to $48.00 and gave the company a "buy" rating in a research note on Thursday, February 8th. Finally, Canaccord Genuity Group dropped their price objective on shares of Arcturus Therapeutics from $87.00 to $86.00 and set a "buy" rating on the stock in a research note on Friday, May 10th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $64.86.

Insider Transactions at Arcturus Therapeutics

In other news, COO Pad Chivukula sold 17,435 shares of Arcturus Therapeutics stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $35.02, for a total value of $610,573.70. Following the transaction, the chief operating officer now owns 473,448 shares of the company's stock, valued at approximately $16,580,148.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 13.80% of the company's stock.

Hedge Funds Weigh In On Arcturus Therapeutics

Several large investors have recently bought and sold shares of the stock. Jacobs Levy Equity Management Inc. raised its stake in Arcturus Therapeutics by 111.0% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 95,924 shares of the biotechnology company's stock valued at $3,239,000 after purchasing an additional 50,470 shares during the last quarter. Caxton Associates LP acquired a new position in shares of Arcturus Therapeutics in the 1st quarter valued at $202,000. Public Employees Retirement System of Ohio raised its stake in shares of Arcturus Therapeutics by 63.8% in the 1st quarter. Public Employees Retirement System of Ohio now owns 4,620 shares of the biotechnology company's stock valued at $156,000 after buying an additional 1,800 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Arcturus Therapeutics by 5.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 17,004 shares of the biotechnology company's stock valued at $575,000 after buying an additional 922 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co raised its stake in shares of Arcturus Therapeutics by 10.5% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,492 shares of the biotechnology company's stock valued at $152,000 after buying an additional 428 shares in the last quarter. 94.54% of the stock is currently owned by institutional investors and hedge funds.

Arcturus Therapeutics Price Performance

Shares of NASDAQ ARCT traded up $1.48 during trading hours on Thursday, hitting $30.50. 347,672 shares of the stock were exchanged, compared to its average volume of 460,621. The company's 50 day moving average is $30.90 and its 200 day moving average is $30.42. The firm has a market capitalization of $821.37 million, a P/E ratio of -7.80 and a beta of 2.65. Arcturus Therapeutics has a one year low of $17.52 and a one year high of $43.81.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last released its earnings results on Thursday, March 7th. The biotechnology company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($1.69) by $1.37. The firm had revenue of $33.99 million during the quarter, compared to analysts' expectations of $64.14 million. Arcturus Therapeutics had a negative net margin of 81.59% and a negative return on equity of 37.61%. Research analysts anticipate that Arcturus Therapeutics will post -4.39 earnings per share for the current fiscal year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.